Yokukansan inhibits morphine tolerance and physical dependence in mice: The role of α2A-adrenoceptor

Neuroscience

Volumn 227, Issue , 2012, Pages 336-349

  Nakagawa, T ^a   Nagayasu, K ^a   Nishitani, N ^a   Shirakawa, H ^a   Sekiguchi, K ^b   Ikarashi, Y ^b   Kase, Y ^b   Kaneko, S ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TSUMURA AND CO   (Japan)

Author keywords

2 adrenoceptor; Morphine; Physical dependence; Tolerance; Yokukansan

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; CORYNOXEINE; GEISSOSCHIZINE METHYL ETHER; GLYCYCOUMARIN; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; HIRSUTEINE; HIRSUTINE; ISOCORYNOXEINE; ISORHYNCOPHYLLINE; LIQUIRITIGENIN; LIQUIRITIN; LIQUIRITINAPIOSIDE; MORPHINE; NALOXONE; PLANT MEDICINAL PRODUCT; PRAZOSIN; RHYNCOPHYLLINE; UNCLASSIFIED DRUG; YOHIMBINE; YOKUKANSAN;

ANALGESIC ACTIVITY; ANGELICA; ANGELICA ACUTILOBA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRACTYLODES; ATRACTYLODES LANCEA; BINDING AFFINITY; BINDING COMPETITION; BRAIN STEM; BRAIN TISSUE; BUPLEURUM; BUPLEURUM FALCATUM; CHEMICAL COMPOSITION; CNIDIUM; CNIDIUM OFFICINALE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; GLYCYRRHIZA URALENSIS; IN VIVO STUDY; JUMPING; LIGAND BINDING; MALE; MECHANICAL STIMULATION; MEDULLA OBLONGATA; MORPHINE ADDICTION; MOUSE; NONHUMAN; PAIN THRESHOLD; PONS; PORIA COCOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TREATMENT DURATION; UNCARIA; UNCARIA RHYNCHOPHYLLA; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ADRENERGIC AGENTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ADDICTIVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; DRUGS, CHINESE HERBAL; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; ISOTOPES; MALE; MICE; MORPHINE DEPENDENCE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAIN THRESHOLD; PROPRANOLOL; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-2; TIME FACTORS; TROPANES;

EID: 84868588951     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.09.079     Document Type: Article

References (67)

1. Aghajanian G.K. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 1978, 276:186-188.
2. Akao T., Hayashi T., Kobashi K., Kanaoka M., Kato H., Kobayashi M., Takeda S., Oyama T. Intestinal bacterial hydrolysis is indispensable to absorption of 18 β-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J Pharm Pharmacol 1994, 46:135-137.
3. 2-adrenoceptor gene expression in hippocampus. Neurosci Lett 2007, 412:163-167.
4. Ambrosio E., Iglesias V., García-Lecumberri C., Orensanz L., Alguacil L.F. Effect of yohimbine on the development of morphine dependence in the rat: lack of involvement of cortical beta-adrenoceptor modifications. Pharmacol Biochem Behav 1997, 56:487-491.
5. 2C adrenoceptors. Cell Signal 2002, 14:829-837.
6. Bailey C.P., Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005, 5:60-68.
7. 2-adrenoceptor subtypes or an additional non-adrenergic interaction?. Life Sci 1988, 43:83-92.
8. Christie M.J. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008, 154:384-396.
9. Dossin O., Hanoun N., Zajac J.M. Involvement of locus coeruleus projections in opiate withdrawal but not in opiate tolerance in mice. Eur J Pharmacol 1996, 308:271-274.
10. Dwoskin L.P., Neal B.S., Sparber S.B. Yohimbine exacerbates and clonidine attenuates acute morphine withdrawal in rats. Eur J Pharmacol 1983, 90:269-273.
11. 2A receptors in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1516-1520.
12. Egashira N., Nogami A., Iwasaki K., Ishibashi A., Uchida N., Takasaki K., Mishima K., Nishimura R., Oishi R., Fujiwara M. Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: possible involvement of GABAA-benzodiazepine receptor complex. J Pharmacol Sci 2011, 116:316-320.
13. El-Kadi A.O., Sharif S.I. The influence of chronic treatment with clonidine, yohimbine and idazoxan on morphine withdrawal. Psychopharmacology 1997, 132:67-73.
14. Fairbanks C.A., Stone L.S., Wilcox G.L. Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacol Ther 2009, 123:224-238.
15. Fairbanks C.A., Wilcox G.L. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J Pharmacol Exp Ther 1999, 288:1107-1116.
16. Fujiwara H., Takayama S., Iwasaki K., Tabuchi M., Yamaguchi T., Sekiguchi K., Ikarashi Y., Kudo Y., Kase Y., Arai H., Yaegashi N. Yokukansan, a traditional Japanese medicine, ameliorates memory disturbance and abnormal social interaction with anti-aggregation effect of cerebral amyloid β proteins in amyloid precursor protein transgenic mice. Neuroscience 2011, 180:305-313.
17. Galli A., DeFelice L.J., Duke B.J., Moore K.R., Blakely R.D. Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol 1995, 198:2197-2212.
18. 3H-prazosin to rat brain α-adrenergic receptors. Eur J Pharmacol 1979, 55:323-326.
19. Hattori M., Sakamoto T., Kobashi K., Namba T. Metabolism of glycyrrhizin by human intestinal flora. Planta Med 1983, 48:38-42.
20. Hui K.S., Roberts M.B. An improved implantation pellet for rapid induction of morphine dependence in mice. J Pharm Pharmacol 1975, 27:569-573.
21. Iglesias V., Alguacil L.F., Alamo C., Cuenca E. Effects of yohimbine on morphine analgesia and physical dependence in the rat. Eur J Pharmacol 1992, 211:35-38.
22. Ikarashi Y., Iizuka S., Imamura S., Yamaguchi T., Sekiguchi K., Kanno H., Kawakami Z., Yuzurihara M., Kase Y., Takeda S. Effects of yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats. Biol Pharm Bull 2009, 32:1701-1709.
23. Imamura S., Tabuchi M., Kushida H., Nishi A., Kanno H., Yamaguchi T., Sekiguchi K., Ikarashi Y., Kase Y. The blood-brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol 2011, 31:787-793.
24. Iwasaki K., Satoh-Nakagawa T., Maruyama M., Monma Y., Nemoto M., Tomita N., Tanji H., Fujiwara H., Seki T., Fujii M., Arai H., Sasaki H. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005, 66:248-252.
25. Iwasaki K., Maruyama M., Tomita N., Furukawa K., Nemoto M., Fujiwara H., Seki T., Fujii M., Kodama M., Arai H. Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry 2005, 66:1612-1613.
26. Kanno H., Sekiguchi K., Yamaguchi T., Terawaki K., Yuzurihara M., Kase Y., Ikarashi Y. Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats. J Pharm Pharmacol 2009, 61:1249-1256.
27. Kawakami Z., Kanno H., Ueki T., Terawaki K., Tabuchi M., Ikarashi Y., Kase Y. Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells. Neuroscience 2009, 159:1397-1407.
28. Kawakami Z., Ikarashi Y., Kase Y. Glycyrrhizin and its metabolite 18β-glycyrrhetinic acid in Glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. Eur J Pharmacol 2010, 626:154-158.
29. Kawakami Z., Ikarashi Y., Kase Y. Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan. Cell Mol Neurobiol 2011, 31:1203-1212.
30. Kosten T.A. Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal. Eur J Pharmacol 1994, 254:59-63.
31. Lobmaier P., Gossop M., Waal H., Bramness J. The pharmacological treatment of opioid addiction - a clinical perspective. Eur J Clin Pharmacol 2010, 66:537-545.
32. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 1997, 21:91-104.
33. Mizoguchi K., Tanaka Y., Tabira T. Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. J Ethnopharmacol 2010, 127:70-76.
34. Mizoguchi K., Shoji H., Tanaka Y., Tabira T. Ameliorative effect of traditional Japanese medicine yokukansan on age-related impairments of working memory and reversal learning in rats. Neuroscience 2011, 177:127-137.
35. Mizukami K., Asada T., Kinoshita T., Tanaka K., Sonohara K., Nakai R., Yamaguchi K., Hanyu H., Kanaya K., Takao T., Okada M., Kudo S., Kotoku H., Iwakiri M., Kurita H., Miyamura T., Kawasaki Y., Omori K., Shiozaki K., Odawara T., Suzuki T., Yamada S., Nakamura Y., Toba K. A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol 2009, 12:191-199.
36. Nader K., van der Kooy D. Clonidine antagonizes the aversive effects of opiate withdrawal and the rewarding effects of morphine only in opiate withdrawal rats. Behav Neurosci 1996, 110:389-400.
37. 3 receptor. Br J Pharmacol 1995, 116:2661-2666.
38. Nakagawa T., Ozawa T., Shige K., Yamamoto R., Minami M., Satoh M. Inhibition of morphine tolerance and dependence by MS-153, a glutamate transporter activator. Eur J Pharmacol 2001, 419:39-45.
39. Nakamura Y., Tajima K., Kawagoe I., Kanai M., Mitsuhata H. Efficacy of traditional herbal medicine, Yokukansan on patients with neuropathic pain. Masui 2009, 58:1248-1255.
40. 1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan. Neuroscience 2012, 207:124-136.
41. Ozawa T., Nakagawa T., Shige K., Minami M., Satoh M. Changes in the expression of glial glutamate transporters in the rat brain accompanied with morphine dependence and naloxone-precipitated withdrawal. Brain Res 2001, 905:254-258.
42. Ozawa T., Nakagawa T., Sekiya Y., Minami M., Satoh M. Effect of gene transfer of GLT-1, a glutamate transporter, into the locus coeruleus by recombinant adenoviruses on morphine physical dependence in rats. Eur J Neurosci 2004, 19:221-226.
43. 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol 2004, 497:161-171.
44. Redmond D.E., Huang Y.H. The primate locus coeruleus and effects of clonidine on opiate withdrawal. J Clin Psychiatry 1982, 43:25-29.
45. Sekiya Y., Nakagawa T., Ozawa T., Minami M., Satoh M. Facilitation of morphine withdrawal symptoms and morphine-induced conditioned place preference by a glutamate transporter inhibitor dl-threo-β-benzyloxyaspartate in rats. Eur J Pharmacol 2004, 485:201-210.
46. 2-adrenoceptors. Behav Pharmacol 1996, 7:334-340.
47. Shearman G.T., Lal H., Ursillo R.C. Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacol Biochem Behav 1980, 12:573-575.
48. 2-adrenoceptor number and function in brains of morphine-dependent rats. Eur J Pharmacol 1989, 161:111-119.
49. Streel E., Dan B., Campanella S., Meyvaert A., Hanak C., Pelc I., Verbanck P. A pharmacological modulation of opiate withdrawal using an up-/down-regulation of the noradrenergic system in opiate-dependent rats. Int J Neuropsychopharmacol 2006, 9:621-626.
50. Suzuki Y, Mitsuhata H, Yuzurihara M, Kase Y (2012) Antiallodynic effect of herbal medicine yokukansan on peripheral neuropathy in rats with chronic constriction injury. Evid Based Complement Altern Med 953459, doi:10.1155/2012/953459.
51. Tabuchi M., Yamaguchi T., Iizuka S., Imamura S., Ikarashi Y., Kase Y. Ameliorative effects of yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease. J Ethnopharmacol 2009, 122:157-162.
52. Tabuchi M., Imamura S., Kawakami Z., Ikarashi Y., Kase Y. The blood-brain barrier permeability of 18β-glycyrrhetinic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a aonstituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol 2012, 32:1139-1146.
53. Takeda S., Ishthara K., Wakui Y., Amagaya S., Maruno M., Akao T., Kobashi K. Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J Pharm Pharmacol 1996, 48:902-905.
54. Takeda A., Itoh H., Tamano H., Yuzurihara M., Oku N. Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. Nutr Neurosci 2008, 11:41-46.
55. Tamano H., Kan F., Oku N., Takeda A. Ameliorative effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient young mice. Brain Res Bull 2010, 83:351-355.
56. Taylor J.R., Lewis V.O., Elsworth J.D., Pivirotto P., Roth R.H., Redmond D.E. Yohimbine co-treatment during chronic morphine administration attenuates naloxone-precipitated withdrawal without diminishing tail-flick analgesia in rats. Psychopharmacology 1991, 103:407-414.
57. Terawaki K., Ikarashi Y., Sekiguchi K., Nakai Y., Kase Y. Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol 2010, 127:306-312.
58. Tseng L.F., Loh H.H., Wei E.T. Effects of clonidine on morphine withdrawal signs in the rat. Eur J Pharmacol 1975, 30:93-99.
59. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991, 251:85-87.
60. Uchida N., Egashira N., Iwasaki K., Ishibashi A., Tashiro R., Nogami A., Manome N., Abe M., Takasaki K., Mishima K., Takata J., Oishi R., Nishimura R., Fujiwara M. Yokukansan inhibits social isolation-induced aggression and methamphetamine-induced hyperlocomotion in rodents. Biol Pharm Bull 2009, 32:372-375.
61. Ueda T., Ugawa S., Ishida Y., Shimada S. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. Eur J Pharmacol 2011, 671:79-86.
62. 3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther 1994, 271:1558-1565.
63. 2C-adrenoceptors, 1998. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur J Pharmacol 1998, 343:93-101.
64. 2-noradrenergic receptors in brain, heart, and lung membranes. J Biol Chem 1978, 253:5090-5102.
65. van Bockstaele E.J., Menko A.S., Drolet G. Neuroadaptive responses in brainstem noradrenergic nuclei following chronic morphine exposure. Mol Neurobiol 2001, 23:155-171.
66. Yamada M., Hayashida M., Zhao Q., Shibahara N., Tanaka K., Miyata T., Matsumoto K. Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice. J Ethnopharmacol 2011, 135:737-746.
67. Yamamura Y., Kawakami J., Santa T., Kotaki H., Uchino K., Sawada Y., Tanaka N., Iga T. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. J Pharm Sci 1992, 81:1042-1046.